...
首页> 外文期刊>Israel journal of chemistry >Light-Activated Pharmaceuticals in Therapy and Diagnosis
【24h】

Light-Activated Pharmaceuticals in Therapy and Diagnosis

机译:在治疗和诊断方面的光激活药物

获取原文
获取原文并翻译 | 示例
           

摘要

Light-activated contrast and therapeutic agents provide inherent selectivity since their response is constrained by a light field. This unique property makes such compounds highly attractive for applications in the research and clinical arenas. With advances in light-based technologies and integration with standard methods, the utilization of light-activated molecules (LAM) for therapy and diagnostics has entered a new phase during the last decade. Although the molecular arsenal and applications in the clinic are not yet achieving their full potential and are still largely at the experimental preclinical and clinical stage, the capacity of these molecules to enable cell and tissue destruction in a spatially confined manner has been demonstrated unequivocally. It is generally accepted that in most cases cell killing and tissue destruction occur via reactive oxygen species (ROS) rather than by the primarily excited sensitizers. This understanding provided the rationale for defining the emerging therapeutic approach as "photodynamic therapy" (PDT) where "photo" refers to light activation and "dynamic" reflects the mobilization of reactivity from the primary reactant to molecular oxygen through electron- (Type I) or energy-transfer (Type II).
机译:光激活的对比度和治疗剂具有固有的选择性,因为它们的响应受到光场的约束。这种独特的属性使这种化合物对研究和临床领域的应用具有很高的吸引力。随着基于光的技术的进步和与标准方法的整合,在过去的十年中,光激活分子(LAM)用于治疗和诊断已经进入了新阶段。尽管分子武器库和诊所中的应用尚未达到其全部潜力,并且仍在实验性的临床前和临床阶段,但这些分子能够以空间上限制的方式使细胞和组织破坏造成细胞和组织破坏。人们普遍认为,在大多数情况下,细胞杀死和组织破坏是通过活性氧(ROS)而不是主要激发敏化剂发生的。这种理解提供了将新兴的治疗方法定义为“光动力疗法”(PDT)的理由,其中“照片”是指光激活和“动态”反映了通过电子(I型I)通过电子(I)的分子氧对分子氧的反应性的动员化。或能量转移(II型)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号